Small Cell Lung Cancer Sclc Treatment Market Scope And Analysis

  • Report Code : TIPRE00034730
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Small Cell Lung Cancer (SCLC) Treatment Market Analysis, Trends, and Scope 2021 to 2022

Buy Now

Small Cell Lung Cancer (SCLC) Treatment Market Report Small Cell Lung Cancer (SCLC) Treatment Market Size and Share Small Cell Lung Cancer (SCLC) Treatment Market Scope and Analysis

Small Cell Lung Cancer (SCLC) Treatment Market Report Scope

Report Attribute Details
Market size in 2022 US$ 4,480.85 Million
Market Size by 2030 US$ 9,173.60 Million
Global CAGR (2022 - 2030) 9.4%
Historical Data 2020-2022
Forecast period 2022-2030
Segments Covered By Treatment
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
By Stage
  • Limited Stage and Extensive Stage
By End User
  • Hospitals
  • Specialty Clinics
  • Homecare Settings
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • F Hoffmann La Roche
  • Bristol Myers Squibb
  • AstraZeneca
  • Jazz Pharmaceuticals plc
  • Merck KgaA
  • Dr Reddy s Laboratories Inc
  • GlaxoSmithKline GSK
  • Pfizer
  • Regeneron

    • Competitive Landscape and Key Companies:

    F. Hoffmann-La Roche, Bristol Myers Squibb, AstraZeneca, Jazz Pharmaceuticals plc, Merck KgaA, Dr. Reddy's Laboratories, Inc., GlaxoSmithKline (GSK), Pfizer, Regeneron, and Janssen are a few of the prominent SCLC treatment manufacturers operating in the global SCLC treatment market. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the increasing consumer demand worldwide and grow their product range in specialty portfolios. In November 2022, Regeneron Pharmaceuticals, Inc. announced approval for the USFDA's "PD-1 inhibitor "Libtayo (cemiplimab-rwlc)" in combination with platinum-based chemotherapy intended for the first-line treatment of adult patients. Libtayo is also approved for extending the survival of patients suffering from advanced SCLC.